We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

We recently published a list of 13 High Growth Large Cap Stocks To Invest In. In this article, we are going to take a look at ...

This was the stock's fourth consecutive day of gains.

In a regulatory filing, Vertex Pharmaceuticals (VRTX) chief scientific officer David Altshuler disclosed the sale of 3,231 common shares of the ...

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a ...

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $502.92, signifying a +1.51% move from its prior day's close. We recently published a list of the 11 Best Pharma Stocks to Buy ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...